To overview |
|
| | |||
| 9-Month Report |
| Carl Zeiss Meditec remains on growth course | Downloads and Links | |||||||||||||||||||||||||||||||
| Positive development in all strategic business units and reporting regions / Forecast for whole year confirmed | RTF Documents
english (7886 KB)Further Information 
Deutsche Version | |||||||||||||||||||||||||||||||
| JENA/Germany, 14.08.2012. Medical technology provider Carl Zeiss Meditec AG continued on its growth course in the third quarter of financial year 2011/2012. Revenue climbed 13.6 percent during the past nine months of the financial year, compared with the same period of the previous year, to € 630.8 million; this growth is attributable to all business areas and all regions. EBIT increased from € 75.7 million to € 88.6 million. The Company confirms its revenue forecast for the whole year. "In spite of an increasingly difficult situation in the global economy, we achieved a solid result, with double-digit revenue growth, and stick firmly to our revenue forecast for the year as a whole," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. The Company anticipates revenue of between € 830 and € 860 million in financial year 2011/2012, which would correspond to a growth corridor of 9 to 13 percent. "What is positive is that all strategic business units and reporting regions continued to contribute to our result. We consider ourselves well equipped for the future with our diversified product portfolio, which ranges from ophthalmology, through microsurgery, to innovative applications in radiation therapy, the expansion of our solutions business, and our service range," says Monz. The Company is therefore firmly adhering to its previously forecast target of an EBIT margin of 15 percent by 2015. Profitability was 14.0 percent and thus 0.4 percentage points higher than in the same period of the previous year. Key figures by region and business units at a glance All regions and strategic business units contribu- ted to the positive development of business. With growth of 14.1 percent, accompanied by persis- tently strong demand from the USA and good contributions to revenue from Latin America, the Americas region grew the most in the 9-month period. The Asia/Pacific (APAC) region grew by 13.7 percent. Bolstered by a positive new orders situation, this region still holds great potential for growth. The EMEA region, with particularly robust demand from Germany and Russia – despite uncertain general conditions, especially in Southern Europe – generated a total of 12.9 percent more revenue than in the same period of the previous year. In terms of the strategic business units, the Microsurgery SBU proved, once again, to be a sales magnet, achieving growth of 21.6 percent. Innovative products like surgical microscopes for neurosurgery continued to be in particular de- mand. In Surgical Ophthalmology, the growth of 13.3 percent was achieved in particular from the business with intraocular lenses for minimally invasive cataract surgery and from a sales acqui- sition in Spain. Finally, the persistently strong demand for refractive lasers, which enable a completely new form of treatment for ametropia, formed the basis for the growth of 6.1 percent in the Ophthalmic Systems business unit. Revenue by strategic business unit
Revenue by region
Jann Gerrit Ohlendorf Director Corporate Communications Carl Zeiss Meditec AG Phone: +49 3641 220-331 Fax: +49 3641 220-332 E-Mail: 
press@meditec.zeiss.comHenriette Meyer Director Investor Relations Carl Zeiss Meditec AG Tel.: +49 3641 220-106 Fax: E-Mail: investors@meditec.zeiss.com
Number: 0076-2012-ENG OP |
|
